CEPI (Coalition for Epidemic Preparedness Innovations)
Gro Anett Nicolaysen serves as the Government Country Lead and Government Resource Mobilization Lead at CEPI, where responsibilities include developing international relations and securing funding partnerships. Previous roles include Regional Corporate Affairs and Business Development Manager at Salcon Petroleum Services, Business Analyst at DNV GL, and various positions at the Norwegian Red Cross, including Regional Representative for Asia and Country Manager for Indonesia. Gro Anett has also worked with UNHCR and UNOCHA in protection-focused roles and has extensive experience in program development and management within humanitarian contexts. Academic credentials include an MSc in Political Sociology from The London School of Economics and Political Science and an undergraduate degree in Social Anthropology and Social Psychology from the University of Oslo.
This person is not in the org chart
This person is not in any teams
CEPI (Coalition for Epidemic Preparedness Innovations)
2 followers
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines against future epidemics. Prior to COVID-19, CEPI’s work focused on developing vaccines against the Ebola Virus Disease, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus. It has over 20 vaccine candidates against these pathogens in development. CEPI has also invested in new platform technologies for rapid vaccine development against unknown pathogens (Disease X). During the COVID-19 pandemic, CEPI initiated multiple programmes to develop vaccines against SARS-CoV-2 and its variants with a focus on speed, scale, and access. These programmes leverage the rapid response platforms developed by CEPI’s partners prior to the emergence of COVID-19, as well as new collaborations. The aim is to advance clinical development of a diverse portfolio of safe and effective COVID-19 candidates and to enable fair allocation of these vaccines worldwide through COVAX. CEPI’s 5-year plan lays out a $3.5 billion roadmap to compress vaccine development timelines to 100 days, develop a broadly protective vaccine against COVID-19 and other Betacoronaviruses, and create a “library” of vaccine candidates for use against known and unknown pathogens. The plan is available at www.endpandemics.cepi.net